Scientific rationale for extrapolation of biosimilar data across cancer indications: case study of CT-P10.

Abstract

For a biosimilar to gain regulatory approval, a comprehensive comparability exercise must demonstrate that it is highly similar to its originator biologic, or reference product. Once biosimilarity has been shown, it is possible to approve the biosimilar for additional indications held by the reference product, without clinical trials in these indications. Extrapolation of clinical data is permitted by regulatory agencies as long as it is scientifically justified. CT-P10, a biosimilar of rituximab, was recently approved in Europe for all indications held by its reference product, incorporating both autoimmune diseases and hematological cancers. Here, we review the scientific rationale for extrapolation in biosimilar development using the example of CT-P10 as a case study.

• Authors: Michinori Ogura, Bertrand Coiffier, Hyuk-Chan Kwon, Sang Wook Yoon
• Journal: Future oncology (London, England) (Future Oncol) Vol. 13 Issue 15s Pg. 45-53 (May 2017) ISSN: 1744-8301 [Electronic] England
• PMID: 28482699 (Publication Type: Journal Article, Review)

Chemical References

• Antibodies, Monoclonal
• Antineoplastic Agents
• Biosimilar Pharmaceuticals
• Rituximab

Topics

• Antibodies, Monoclonal (pharmacology, therapeutic use)
• Antineoplastic Agents (pharmacology, therapeutic use)
• Biosimilar Pharmaceuticals (pharmacology, standards, therapeutic use)
• Drug Approval
• Humans
• Neoplasms (drug therapy, pathology)
• Rituximab (pharmacology, therapeutic use)
• Treatment Outcome